33 results about "Central retinal vein occlusion" patented technology

A method of treatment of ocular compartment syndromes is provided. Known ocular compartment syndromes include central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), non-arteritic anterior ischemic optic neuropathy (NAAION), and papilledema. One or more lasers known to have photoablative, photodisruptive, or photocoagulative effects are used to decompress the ocular compartment syndromes. The method includes the steps of positioning a patient beneath an operative microscope (110) and one or more lasers (108,109,111), positioning a fixation ring (104) on the operative eye (102) identifying the site of the occlusion using an operative microscope (110), and directing laser energy at the target tissue responsible for the occlusion. A display (112) is provided to guide the surgeon performing the laser treatments. A microscope and laser control system (114) is provided to allow the surgeon to control the operative microscope (110) and the lasers (108,109,111).

There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease.

The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The present invention relates to the field of medicine, and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, wherein the pharmaceutical composition comprises a ginsenoside monomer Rg1 and a ginsenoside monomer Rb1, a weight ratio of the Rg1 to the Rb1 is 1:4-4:1. The ginsenoside composition of the present invention has the following advantages that:the pharmaceutical composition of the present invention has effects of blood activating and stasis removing, blood circulation promoting and collateral activating, and can be applicable for obstruction of collaterals by blood stasis, apoplectic hemiplegia, chest stuffiness and pains, and central retinal vein occlusion; the efficacy of the pharmaceutical composition is definite; the adverse reaction rate is significantly reduced; when the weight ratio of the Rg1 to the Rb1 is 1:4, the LD50 of the ginsenoside composition is more than 1000 mg/kg, and is significantly higher than the LD50 of panax notoginsenosidum; the ginsenoside composition provides the significant inhibition effect for thrombosis, and the anticoagulant effect so as to essentially improve various damages of ischemic cardiovascular and cerebrovascular disease patients due to ischemia.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention discloses a traditional Chinese medicine for treating central retinal vein obstruction. The traditional Chinese medicine is characterized by being prepared from the following medicinal materials in parts by weight: 8-10 parts of peach seeds, 8-10 parts of safflower, 12-15 parts of angelica, 12-15 parts of rehmannia root, 8-10 parts of Szechuan lovage rhizome, 8-10 parts of red peony root, 5-6 parts of Chinese thorowax root, 8-10 parts of achyranthes root, 8-10 parts of horse-tail club moss, 5-6 parts of platycodon grandiflorum, 2-3 parts of licorice, 12-15 parts of Chinese arborvitae twigs, 8-10 parts of motherwort fruits, 0-30 parts of clematis finetiana and 0-9 parts of straight-flowered corydalis. A preparation method comprises the steps of weighing the medicinal materials, putting the medicinal materials into a container, adding water of which the quantity is 8 times that of the medicinal materials, decocting for 1.5 hours, and filtering; adding water of which the quantity is 6 times that of filter residues into the filter residues, decocting for 1 hour, and filtering; and combining the filtrates, concentrating, drying, and filling capsule shells with the dried mixture. Clinical experiments prove that the traditional Chinese medicine achieves a significant effect of treating the central retinal vein obstruction by selecting the appropriate medicinal materials and the ratio thereof, is safe and does not have toxic or side effect.

The invention discloses a medicine for treating central retinal vein occlusion and a preparation method thereof. The medicine is mainly prepared from the following components by weight: peach kernels, angelica sinensis, salviae miltiorrhizae, kudzuvine roots, radix achyranthis bidentatae, concha haliotidis, fructus forsythia, pollen typhae, semen cassia, selfheal, selfheal, liquidambar formosana hance, tortoise shells, golden cypress, periostracum cicada, periostracum cicada, dried radix rehmanniae, glossy privet fruits, motherwort fruits, ligusticum wallichii, rhizoma cyperi and flowers carthami. The medicine disclosed by the invention has the functions of calming the liver and suppressing yang, breaking blood and removing blood stasis, clearing heat, improving eyesight and nourishing yin to lessen fire, and is fast to take effect and good in curative effect for treating central retinal vein occlusion, and the central retinal vein occlusion does not relapse.

A traditional Chinese medicine preparation is prepared from the following raw materials by weight: 25-30 g of prepared rehmannia root, 15-20 g of angelica sinensis, 10-15 g of radix paeoniae rubra, 8-10 g of rhizoma chuanxiong, 12-18 g of radix bupleuri, 15-20 g of platycodon grandiflorum, 15-20 g of fructus aurantii immaturus, 20-25 g of semen persicae, 15-20 g of radix curcumae, 12-18 g of salvia miltiorrhiza, 12-15 g of caulis spatholobi, 10-15 g of fructus lycii, and 6-10 g of licorice. The traditional Chinese medicine preparation is capable of regulating liver and promoting qi circulation, promoting blood circulation to remove blood stasis, and improving eyesight and dredging collaterals, and plays a role in treating both symptoms and root causes on the retinal vein occlusion. The traditional Chinese medicine preparation has the following clinical effects: 1, the traditional Chinese medicine preparation effectively treats the retinal vein occlusion, the clinical healing and conspicuous effect rate is 66.6%, and the total clinical effective rate is 93.3%; 2, the traditional Chinese medicine preparation can improve eyesight, improves retinal microcirculation and retinal ischemia reperfusion, and promotes retinal hemorrhage and exudation absorption, so as to achieve the purpose of treating the retinal vein occlusion; and 3, the traditional Chinese medicine preparation is convenient to take, and has no toxic or side effect.

The invention relates to a Chinese medicinal composition for treating ocular fundus vascular diseases, belonging to the medical field. A Chinese medicinal composition is prepared from Astragalus membranaceus, honeysuckle, cortex phellodendron, atractylodes atractylodes, radix scrophulariae, angelica sinensis, radix paeoniae alba andcoix seed. As proved by pharmacodynamics and clinical trials, thatcomposition of the invention can improve the phenomenon of retinal hemorrhage and edema cause by diabetes, and can also treat or alleviate retinal microangioma, hemorrhage, exudation and special changes of veins in retinal vein occlusion and the like. The traditional Chinese medicine composition of the invention has comprehensive effect, low toxicity and side effect, and better therapeutic effectthan the existing medicine when used for treating fundus retinopathy, and has broad market prospect.

The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

The present invention teaches a method and new use for anticoagulant compounds for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) and other conditions. CRVO and BRVO represent debilitating conditions for which there is currently no effective therapy. The present invention teaches a new therapy, including new uses for existing pharmacological agents, comprising enoxaparin sodium, warfarin, clopidrogel, and others, in the treatment of these and other conditions.

Because 3-[(3S, 4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.